Vol 14, No 1 (2017)
Review paper
Published online: 2017-03-01
Page views
1454
Article views/downloads
50162
The use of vortioxetine for the treatment of depressive disorders
Psychiatria 2017;14(1):7-20.
Abstract
Despite many years of research, the effectiveness of antidepressant treatment is still unsatisfactory, and the criteria for this effectiveness are the subject of discussion and does not reflect the subjective feeling of the patient’s health. Another major problem seems to be insufficient tolerance of antidepressants (AD), which may result in non-compliance or premature discontinuation of treatment and contribute to the intensification of functional impairment resulting from residual symptoms of depression after the resolution of an acute episode. These data justify the need to research for new mechanisms of AD’s action, increasing the chances of favorable clinical profile. A good example is multimodal drugs which have simultaneously at least two different mechanisms of action (eg. reuptake inhibition and receptor activity) and at least two binding sites on neurons. Such multi-faceted mechanism may be associated with a stronger therapeutic effect, action on a broader range of symptoms and fewer side effects. Vortioxetine is she representative of this pharmacological group. In the light of the available data it can be concluded that vortioxetine is an effective, safe and well-tolerated antidepressant. The properties of vortioxetine enable its extensive use in the treatment of acute symptoms and in prevention from recurrence of depressive episodes with a low risk of discontinuation or serious interactions with other drugs . Great issues to be studied are: the effectiveness of vortioxetine in combination with other antidepressants or other drugs from different pharmacological groups in the augmentation of antidepressant treatment and applicability of vortioxetine in the treatment of bipolar depression.
Keywords: vortioxetinedepressionantidepressive agents
References
- Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001; 62 Suppl 16: 5–9.
- Pużyński S. Kryteria oceny efektu przeciwdepresyjnego. W: Pużyński S. Leki przeciwdepresyjne. IPIN, Warszawa, Biblioteka psychiatry, tom 7, 2005: 47–49
- Siwek M. Dekalog leczenia depresji. Dekalog leczenia depresji. ITEM Publishing, Warszawa 2016.
- Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1): 28–40.
- Trivedi MH, Fava M, Wisniewski SR, et al. STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006; 354(12): 1243–1252.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354(12): 1231–1242.
- Siwek M, Grabski B, Dudek D. Psychiatryczne skale oceny w zaburzeniach depresyjnych. W: Red.: Kiejna A, Rybakowski J, Dudek D. Psychiatryczne skale oceny w zaburzeniach afektywnych. Biblioteka Psychiatrii Polskiej, Kraków 2012: 56–90.
- Zimmerman M. Discordance between researchers and patients in defining remission from depression. J Clin Psychiatry. 2012; 73(9): 1262–1263.
- Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011; 41(6): 1165–1174.
- Cartwright C, Gibson K, Read J, et al. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence. 2016; 10: 1401–1407.
- Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015; 145: 43–57.
- Adell A. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. IDrugs. 2010; 13(12): 900–910.
- Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206–3221.
- Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012; 340(3): 666–675.
- Brintellix. For the Treatment of Major Depressive Disorder. Product Monograph. Lundbeck 2015
- Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012; 40(7): 1357–1365.
- Spina E, Santoro V. Drug interactions with vortioxetine, a new multimodal antidepressant. Riv Psichiatr. 2015; 50(5): 210–215.
- Chen G, Lee R, Højer AM, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013; 33(10): 727–736.
- Bazire S. Psychotropic drug directory. Lloyd-Reinhold Communications Ltd, Norwich 2014.
- Woroń J, Siwek M. Zespół serotoninowy. Stany Nagłe po Dyplomie 2017 (w druku).
- Siwek M, Woroń J. Wybrane powikłania i działania niepożądane leczenia normotymicznego. W: Dudek D, Siwek M, Rybakowski J (red.). Choroba afektywna dwubiegunowa: wyzwania terapeutyczne. Termedia Wydawnictwa Medyczne, Poznań 2013; 267–294.
- Areberg J, Petersen KB, Chen G, et al. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol. 2014; 115(6): 552–559.
- Kelliny M, Croarkin PE, Moore KM, et al. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag. 2015; 11: 1193–1212.
- Baldwin DS, Florea I, Jacobsen PL, et al. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord. 2016; 206: 140–150.
- Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(5): 589–600.
- Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22(7): 482–491.
- Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014; 29(3): 138–149.
- Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012; 73(7): 953–959.
- Jacobsen PL, Mahableshwarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015; 76(5): 575–582.
- Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16(2): 313–321.
- Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215–223.
- Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015; 232(12): 2061–2070.
- Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3): 217–226.
- Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry. 2015; 76(5): 583–591.
- Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014; 29(5): 470–482.
- Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry. 2014; 14: 276.
- Fu J, Chen Y. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis. Psychopharmacology (Berl). 2015; 232(1): 7–16.
- Li G, Wang Xu, Ma D. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2016; 12: 523–531.
- Li G, Wang Xu, Ma D. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2016; 36(7): 509–517.
- Meeker AS, Herink MC, Haxby DG, et al. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev. 2015; 4: 21.
- Nomikos GG, Tomori D, Zhong W, et al. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr. 2016 [Epub ahead of print]: 1–15.
- Pae CU, Wang SM, Han C, et al. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci. 2015; 40(3): 174–186.
- Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016; 26(6): 979–993.
- Vieta E, Loft H, Mahableshwarkar AR, et al. P.2.f.023 The efficacy of vortioxetine in the treatment of patients with major depressive disorder (MDD) in short-term placebo-controlled studies: a meta-analysis of 11 studies. European Neuropsychopharmacology. 2014; 24: S465–S466.
- Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014; 29(1): 36–44.
- Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012; 28(10): 1717–1724.
- Filippov G, Christens PF. P.2.b.011 Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder. European Neuropsychopharmacology. 2013; 23: S325.
- Baldwin DS, Hansen T, Florea I. P.2.a.007 Lu AA21004, a multimodal psychotropic agent, in the open-label, long-term treatment of major depressive disorder. European Neuropsychopharmacology. 2012; 22: S227–S228.
- Jacobsen PL, Harper L, Chrones L, et al. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2015; 30(5): 255–264.
- Brignone M, Diamand F, Painchault C, et al. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Curr Med Res Opin. 2016; 32(2): 351–366.
- Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014; 68(1): 60–82.
- Llorca PM, Lançon C, Brignone M, et al. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Curr Med Res Opin. 2014; 30(12): 2589–2606.
- Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016; 30(3): 242–252.
- Dudek D. Leczenie depresji w przebiegu choroby afektywnej jednobiegunowej. W: Jarema M (red.). Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2011: 48–53.
- Jarema M, Dudek D, Czernikiewicz A. Cognitive dysfunctions in depression – underestimated symptom or new dimension? Psychiatria Polska. 2014; 48: 1105–1116.
- Theunissen EL, Street D, Højer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013; 93(6): 493–501.
- McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014; 17(10): 1557–1567.
- McIntyre RS, Harrison J, Loft H, et al. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol. 2016 [Epub ahead of print].
- Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015; 40(8): 2025–2037.
- Kaynak H, Kaynak D, Gözükirmizi E, et al. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004; 5(1): 15–20.
- Wilson S, Højer AM, Buchberg J, et al. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol. 2015; 29(10): 1085–1091.
- Jacobsen PL, Mahableshwarkar AR, Chen Y, et al. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med. 2015; 12(10): 2036–2048.
- Wang Y, Nomikos GG, Karim A, et al. Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study. Clin Pharmacol Drug Dev. 2013; 2(4): 298–309.
